Castleman Disease Pathogenesis
- 1 February 2018
- journal article
- research article
- Published by Elsevier in Hematology/Oncology Clinics of North America
- Vol. 32 (1) , 11-21
Abstract
No abstract availableKeywords
This publication has 55 references indexed in Scilit:
- Interleukin-6 Receptor Polymorphism Is Prevalent in HIV-negative Castleman Disease and Is Associated with Increased Soluble Interleukin-6 Receptor LevelsPLOS ONE, 2013
- Castleman's Disease: Systematic Analysis of 416 Patients from the LiteratureThe Oncologist, 2011
- A2B Adenosine Receptor–Mediated Induction of IL-6 Promotes CKDJournal of the American Society of Nephrology, 2011
- Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra)Molecular Cancer Therapeutics, 2010
- Possible roles of Epstein-Barr virus in Castleman diseaseJournal of Cardiothoracic Surgery, 2009
- IL-1RA Agonist (Anakinra) in the Treatment of Multifocal Castleman DiseaseJournal of Pediatric Hematology/Oncology, 2008
- Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8–specific CD8+ T cellsBlood, 2008
- Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disordersHistopathology, 2006
- Cytogenetic anomalies in hyaline vascular Castleman disease: report of two cases with reappraisal of histogenesisCancer Genetics and Cytogenetics, 2006
- Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice.Journal of Clinical Investigation, 1990